To the Editor: The potential upper gastrointestinal morbidity associated with non-steroidal anti-inflammatory drug (NSAID) misuse is well known.1,2 Recently, Frei and colleagues3 provided an overview of the morbidity and patient characteristics relating to opioid–NSAID misuse; however, they did not identify those patients with NSAID ente
- Careers centre
- MJA Open
- Job Search
Serious morbidity associated with misuse of over-the-counter codeine–ibuprofen analgesics
Rozemary Karamatic, John Croese and Enrico Roche
Med J Aust 2011; 195 (9): 516.
Rozemary Karamatic, Advanced Trainee in Gastroenterology1
John Croese, Senior Medical Officer, Gastroenterology and Hepatology2
Enrico Roche, Director of Gastroenterology1
Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879-888.
Fortun PJ, Hawkey CJ. Non-steroidal anti-inflammatory drugs and the small intestine. Curr Opin Gastroenterol 2007; 23: 134-141.
Frei MY, Nielsen S, Dobbin MDH, Tobin CL. Serious morbidity associated with the misuse of over-the-counter codeine–ibuprofen analgesics: a series of 27 cases. Med J Aust 2010; 193: 294-296.
Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008; 43: 490-496.
Therapeutic Goods Administration. Codeine rescheduling — information for sponsors. 24 Feb 2010. http://www.tga.gov.au/industry/otc-codeine-rescheduling-100224.htm (accessed Sep 2011).
The full contents of this page are only available to subscribers.
Log in to keep reading
* Required information